INO-5401
- Generic Name
- INO-5401
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
Phase 1
Active, not recruiting
- Conditions
- BRCA1/2 Mutation
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 44
- Registration Number
- NCT04367675
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT03502785
- Locations
- 🇺🇸
Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Phase 1
Active, not recruiting
- Conditions
- Glioblastoma
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT03491683
- Locations
- 🇺🇸
University of Pennsylvania Health System: Penn Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Rutgers University - Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath